Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBX7455 in operable stage I-III breast cancer
NCT04139993Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RBX7455 in breast cancer, sponsored by Mayo Clinic. Primary endpoints: Incidence of adverse events at 4 weeks and Intratumoral immunomodulatory effects at 4 weeks. Started Aug 2020; status: terminated.
02
Drugs
RBX7455
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04139993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139993.